Background: Infantile epileptic spasms syndrome (IESS) is a serious disease in infants, and it usually evolves to other epilepsy types or syndromes, especially refractory or super-refractory focal epilepsies. Although adrenocorticotropic hormone (ACTH) is one of the first-line and effective treatment plans for IESS, it has serious side effects and is not sufficiently effective.

Methods: A retrospective study of the clinical outcomes of ACTH combined with magnesium sulfate (MgSO) therapy for IESS in two hospital centers was conducted. The major outcome of the single and combined treatment was evaluated by changes in seizure frequency and improvements in hypsarrhythmia electroencephalography (EEG). To reduce the confounding bias between the two groups, we used SPSS for the propensity score matching (PSM) analysis.

Results: We initially recruited 1205 IESS patients from two Chinese hospitals and treated them with ACTH combined with MgSO and ACTH alone. Only 1005 patients were enrolled in the treatment (ACTH combined with MgSO: 744, ACTH: 261), and both treatment plans had a more than 55% response rate. However, compared to patients treated with ACTH alone, those patients treated with ACTH combined with MgSO had better performance in terms of the seizure frequency and hypsarrhythmia EEG. After PSM, the two groups also showed significant differences in responder rate [70.8% (95% confidence interval, CI) = 66.7%-74.8%) vs. 53.8% (95% CI = 47.4%-60.2%), P < 0.001], seizure frequency (P < 0.001) and hypsarrhythmia EEG resolution (P < 0.001). Notably, multivariate analysis revealed that the lead time to treatment and the number of antiseizure medications taken before treatment were two factors that may affect the clinical outcome. Patients with less than 3 months of lead time responded to the treatment much better than those with > 3 months (P < 0.05). In addition, the overall incidence of adverse reactions in the ACTH combined with MgSO group was much lower than that in the ACTH group (31.4% vs. 63.1%, P < 0.001). During the treatment, only infection (P = 0.045) and hypertension (P = 0.025) were significantly different between the two groups, and no baby died.

Conclusion: Our findings support that ACTH combined with MgSO is a more effective short-term treatment protocol for patients with IESS than ACTH alone, especially for those patients with short lead times to treatment. Video Abstract (MP4 533623 KB).

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11402841PMC
http://dx.doi.org/10.1007/s12519-023-00771-1DOI Listing

Publication Analysis

Top Keywords

acth combined
16
treated acth
12
combined mgso
12
adrenocorticotropic hormone
8
combined magnesium
8
magnesium sulfate
8
infantile epileptic
8
epileptic spasms
8
spasms syndrome
8
iess serious
8

Similar Publications

Background: The treatment of vitiligo is difficult and usually requires prolonged therapy. All exogenous glucocorticoid therapies can lead to the hypothalamic-pituitary-adrenal axis (HPA) suppression. Steroid therapy in the form of an intermittent pulse therapy is a much safer option than daily administration.

View Article and Find Full Text PDF

Desmopressin is a safe and effective secretagogue to replace corticotropin-releasing hormone in petrosal sinus sampling.

Ann Endocrinol (Paris)

December 2024

Aix Marseille Univ, INSERM, UMR1251, Marseille Medical Genetics, Institut MarMaRa, Marseille, France; APHM, Aix Marseille Univ, Department of Endocrinology, Hôpital La Conception, Institut MarMaRa, Marseille, France. Electronic address:

Purpose: Bilateral inferior petrosal sinus sampling (BIPSS) with corticotropin-releasing hormone (CRH) was the gold standard for distinguishing Cushing disease (CD) from ectopic ACTH secretion (EAS). CRH, however, is no longer available.

Objective: To assess the reliability of BIPSS with desmopressin to differentiate CD from EAS.

View Article and Find Full Text PDF

Purpose: Severe Cushing's syndrome (SCS) is a life-threatening endocrine condition that requires prompt medical intervention. Intravenous etomidate infusion is considered to be the most effective in rapid cortisol overproduction inhibition. This single-center retrospective study aimed to present the safety and effectiveness of intravenous, low-dose, lipid-formulated etomidate infusion in patients with SCS.

View Article and Find Full Text PDF

Ethnopharmacological Relevance: The theory of traditional Chinese medicine (TCM) believes that kidney deficiency is the fundamental cause of chronic refractory asthma, accompanied by pathological changes such as airway remodeling and a reduction of endogenous glucocorticoid (GC) synthesis. The combination of Epimedium brevicornum Maxim (EB) and Ligustrum lucidum Ait (LL) is frequently used in TCM for kidney tonifying and the alleviation of asthma symptoms. This approach is based on Pei-Ben formula, a renowned treatment for asthma developed by the distinguished Shanghai Practitioner, Professor Huiguang Xu, over 30 years of clinical experience.

View Article and Find Full Text PDF

Diagnostic Accuracy and Value of CXCR4-targeted PET/MRI Using Ga-Pentixafor for Tumor Localization in Cushing Disease.

Radiology

December 2024

From the Department of Radiology (Yue Wu, S.W., W.R., Z. Yao), Department of Neurosurgery, Shanghai Pituitary Tumor Center (B.Y., Z. Ye, R.H., N.Q., Y. Zhang, X.Y., Z.M., Y. Wang, Y. Zhao, Q.Z.), Department of Nuclear Medicine and PET Center (Yanfei Wu, S.R., Y.G., F.X.), and Department of Endocrinology (M.H., S.Z., Y.Y., H.Y., Z.Z.), Huashan Hospital, Fudan University, 12 Wulumuqi Road, Shanghai 200040, China; Neurosurgical Institute of Fudan University, Shanghai, China (B.Y., Z. Ye, R.H., N.Q., Y. Zhang, X.Y., Z.M., Y. Wang, Y. Zhao, Q.Z.); Shanghai Clinical Medical Center of Neurosurgery, Shanghai, China (B.Y., Z. Ye, R.H., N.Q., Y. Zhang, X.Y., Z.M., Y. Wang, Y. Zhao, Q.Z.); Shanghai Key Laboratory of Brain Function Restoration and Neural Regeneration, Shanghai, China (B.Y., Z. Ye, R.H., N.Q., Y. Zhang, X.Y., Z.M., Y. Wang, Y. Zhao, Q.Z.); and Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Neuroendocrine Unit, Massachusetts General Hospital, and Harvard Medical School, Boston, Mass (Q.Z.).

Background Gallium 68 (Ga) pentixafor has emerged as a potential C-X-C chemokine receptor type 4 (CXCR4)-targeted radiotracer for neuroendocrine tumor, yet its application in Cushing disease remains uncertain. Purpose To assess the diagnostic accuracy and value of Ga-pentixafor PET/MRI in localizing adrenocorticotropic hormone (ACTH)-secreting pituitary tumors in Cushing disease. Materials and Methods A prospective single-center study was conducted from March 2023 to February 2024 in participants with Cushing disease scheduled for surgical pituitary tumor resection.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!